230 related articles for article (PubMed ID: 19509113)
1. Blocking phosphoinositide 3-kinase activity in colorectal cancer cells reduces proliferation but does not increase apoptosis alone or in combination with cytotoxic drugs.
Martin-Fernandez C; Bales J; Hodgkinson C; Welman A; Welham MJ; Dive C; Morrow CJ
Mol Cancer Res; 2009 Jun; 7(6):955-65. PubMed ID: 19509113
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of phosphatidylinositol 3-kinase-Akt signaling blocks growth, promotes apoptosis, and enhances sensitivity of small cell lung cancer cells to chemotherapy.
Krystal GW; Sulanke G; Litz J
Mol Cancer Ther; 2002 Sep; 1(11):913-22. PubMed ID: 12481412
[TBL] [Abstract][Full Text] [Related]
3. Engineering of caveolae-specific self-micellizing anticancer lipid nanoparticles to enhance the chemotherapeutic efficacy of oxaliplatin in colorectal cancer cells.
Sundaramoorthy P; Ramasamy T; Mishra SK; Jeong KY; Yong CS; Kim JO; Kim HM
Acta Biomater; 2016 Sep; 42():220-231. PubMed ID: 27395829
[TBL] [Abstract][Full Text] [Related]
4. PTEN Overexpression Cooperates With Lithium to Reduce the Malignancy and to Increase Cell Death by Apoptosis via PI3K/Akt Suppression in Colorectal Cancer Cells.
de Araujo WM; Robbs BK; Bastos LG; de Souza WF; Vidal FC; Viola JP; Morgado-Diaz JA
J Cell Biochem; 2016 Feb; 117(2):458-69. PubMed ID: 26224641
[TBL] [Abstract][Full Text] [Related]
5. Deoxyshikonin isolated from
Zhu Y; Zhong Y; Long X; Zhu Z; Zhou Y; Ye H; Zeng X; Zheng X
Pharm Biol; 2019 Dec; 57(1):412-423. PubMed ID: 31230505
[No Abstract] [Full Text] [Related]
6. Pre-clinical use of isogenic cell lines and tumours in vitro and in vivo for predictive biomarker discovery; impact of KRAS and PI3KCA mutation status on MEK inhibitor activity is model dependent.
Haagensen EJ; Thomas HD; Mudd C; Tsonou E; Wiggins CM; Maxwell RJ; Moore JD; Newell DR
Eur J Cancer; 2016 Mar; 56():69-76. PubMed ID: 26820797
[TBL] [Abstract][Full Text] [Related]
7. Cudraflavone C Induces Tumor-Specific Apoptosis in Colorectal Cancer Cells through Inhibition of the Phosphoinositide 3-Kinase (PI3K)-AKT Pathway.
Soo HC; Chung FF; Lim KH; Yap VA; Bradshaw TD; Hii LW; Tan SH; See SJ; Tan YF; Leong CO; Mai CW
PLoS One; 2017; 12(1):e0170551. PubMed ID: 28107519
[TBL] [Abstract][Full Text] [Related]
8. LY‑294002 enhances the chemosensitivity of liver cancer to oxaliplatin by blocking the PI3K/AKT/HIF‑1α pathway.
Xu R; Zhang Y; Li A; Ma Y; Cai W; Song L; Xie Y; Zhou S; Cao W; Tang X
Mol Med Rep; 2021 Jul; 24(1):. PubMed ID: 33982772
[TBL] [Abstract][Full Text] [Related]
9. Delicaflavone induces ROS-mediated apoptosis and inhibits PI3K/AKT/mTOR and Ras/MEK/Erk signaling pathways in colorectal cancer cells.
Yao W; Lin Z; Shi P; Chen B; Wang G; Huang J; Sui Y; Liu Q; Li S; Lin X; Liu Q; Yao H
Biochem Pharmacol; 2020 Jan; 171():113680. PubMed ID: 31669234
[TBL] [Abstract][Full Text] [Related]
10. GOLPH3 inhibition reverses oxaliplatin resistance of colon cancer cells via suppression of PI3K/AKT/mTOR pathway.
Yu T; An Q; Cao XL; Yang H; Cui J; Li ZJ; Xiao G
Life Sci; 2020 Nov; 260():118294. PubMed ID: 32818544
[TBL] [Abstract][Full Text] [Related]
11. Aspirin has a better effect on PIK3CA mutant colorectal cancer cells by PI3K/Akt/Raptor pathway.
Chen Z; Wang C; Dong H; Wang X; Gao F; Zhang S; Zhang X
Mol Med; 2020 Jan; 26(1):14. PubMed ID: 32000660
[TBL] [Abstract][Full Text] [Related]
12. Chemosensitization of HT29 and HT29-5FU Cell Lines by a Combination of a Multi-Tyrosine Kinase Inhibitor and 5FU Downregulates ABCC1 and Inhibits PIK3CA in Light of Their Importance in Saudi Colorectal Cancer.
Abdalla AN; Malki WH; Qattan A; Shahid I; Hossain MA; Ahmed M
Molecules; 2021 Jan; 26(2):. PubMed ID: 33440689
[TBL] [Abstract][Full Text] [Related]
13. [Decursin affects proliferation, apoptosis, and migration of colorectal cancer cells through PI3K/Akt signaling pathway].
Yang Y; Hu YE; Zhao MY; Jiang YF; Fu X; You FM
Zhongguo Zhong Yao Za Zhi; 2023 May; 48(9):2334-2342. PubMed ID: 37282862
[TBL] [Abstract][Full Text] [Related]
14. Promethazine inhibits proliferation and promotes apoptosis in colorectal cancer cells by suppressing the PI3K/AKT pathway.
Tan X; Gong L; Li X; Zhang X; Sun J; Luo X; Wang Q; Chen J; Xie L; Han S
Biomed Pharmacother; 2021 Nov; 143():112174. PubMed ID: 34560542
[TBL] [Abstract][Full Text] [Related]
15. Combination PI3K/MEK inhibition promotes tumor apoptosis and regression in PIK3CA wild-type, KRAS mutant colorectal cancer.
Roper J; Sinnamon MJ; Coffee EM; Belmont P; Keung L; Georgeon-Richard L; Wang WV; Faber AC; Yun J; Yilmaz ÖH; Bronson RT; Martin ES; Tsichlis PN; Hung KE
Cancer Lett; 2014 Jun; 347(2):204-11. PubMed ID: 24576621
[TBL] [Abstract][Full Text] [Related]
16. NDAT Targets PI3K-Mediated PD-L1 Upregulation to Reduce Proliferation in Gefitinib-Resistant Colorectal Cancer.
Huang TY; Chang TC; Chin YT; Pan YS; Chang WJ; Liu FC; Hastuti ED; Chiu SJ; Wang SH; Changou CA; Li ZL; Chen YR; Chu HR; Shih YJ; Cheng RH; Wu A; Lin HY; Wang K; Whang-Peng J; Mousa SA; Davis PJ
Cells; 2020 Aug; 9(8):. PubMed ID: 32756527
[TBL] [Abstract][Full Text] [Related]
17. Pro-survival responses to the dual inhibition of anti-apoptotic Bcl-2 family proteins and mTOR-mediated signaling in hypoxic colorectal carcinoma cells.
Risberg K; Redalen KR; Sønstevold L; Bjørnetrø T; Sølvernes J; Ree AH
BMC Cancer; 2016 Jul; 16():531. PubMed ID: 27461218
[TBL] [Abstract][Full Text] [Related]
18. Combined PI3K and CDK2 inhibition induces cell death and enhances in vivo antitumour activity in colorectal cancer.
Beale G; Haagensen EJ; Thomas HD; Wang LZ; Revill CH; Payne SL; Golding BT; Hardcastle IR; Newell DR; Griffin RJ; Cano C
Br J Cancer; 2016 Sep; 115(6):682-90. PubMed ID: 27529512
[TBL] [Abstract][Full Text] [Related]
19. Exclusive inhibition of PI3K/Akt/mTOR signaling is not sufficient to prevent PDGF-mediated effects on glycolysis and proliferation in colorectal cancer.
Moench R; Grimmig T; Kannen V; Tripathi S; Faber M; Moll EM; Chandraker A; Lissner R; Germer CT; Waaga-Gasser AM; Gasser M
Oncotarget; 2016 Oct; 7(42):68749-68767. PubMed ID: 27626684
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.
Martinelli E; Troiani T; D'Aiuto E; Morgillo F; Vitagliano D; Capasso A; Costantino S; Ciuffreda LP; Merolla F; Vecchione L; De Vriendt V; Tejpar S; Nappi A; Sforza V; Martini G; Berrino L; De Palma R; Ciardiello F
Int J Cancer; 2013 Nov; 133(9):2089-101. PubMed ID: 23629727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]